New hope for slowing kidney disease progression
NCT ID NCT06391450
Summary
This study is testing whether a diabetes drug called empagliflozin is safe and can help slow the progression of a genetic kidney disease called ADPKD. It involves 44 adults with rapidly progressing disease, some of whom are already taking the standard medication. Researchers will measure changes in kidney size and function over 18 months to see if empagliflozin provides additional benefit.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany
Conditions
Explore the condition pages connected to this study.